NeuroMetrix Reports Executive Stock Transactions During May 2016
WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell® Wearable Pain Relief Technology™, reported purchases during May 2016 of the company’s common stock by its Chief Executive Officer, Dr. Shai N. Gozani; its Chief Financial Officer, Thomas T. Higgins; and its SVP and General Manager, Consumer, Frank McGillin. Details of these transactions may be found on the U.S. Securities and Exchange Commission’s EDGAR website at the following links:
About Quell
Quell utilizes NeuroMetrix's patented neurostimulation technology to provide widespread relief from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell includes a smartphone app that tracks and personalizes their pain therapy. Quell was recently awarded the Innovation Award at SXSW for best Wearable Technology. It is available for purchase at www.QuellRelief.com, selected retailers and healthcare professionals.
About NeuroMetrix
NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
Contacts
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
neurometrix.ir@neurometrix.com